Theratechnologies Inc T.TH

ASCO June 2023

[scarlet1967]

https://clin.larvol.com/abstract-detail/ASCO%202023/65034380

[SPCEO1]

I suspect we would all like to see some phase 1b data at this time but it will still be interesting to see what they have to say in this presentation on the phase 1a data. Something is better than nothing but the phase 1b data is what really matters as it may give us greater insight into what the critical restarted trial will have to overcome. Of course, it seemed like the phase 1b may have also

[Trogarzon]

They could win a Nobel prize and be on the cover on the New England journal that the only thing that matters for shareholder would'nt move, the stock price.  I recall in the good old times when companies reporter once a year and that the fist question at AGMs where, hey Mr CEO where do you see my stock price next year.  But no not in this woke world where you could offend someone by

[Trogarzon]

I'm disgrunted with the company and with it's shareholders now because we're all like hey we're all going to be alright.. trust life.  In my book they are past that time, it's game over for the board and for our dedicated management.  I'm hiring Remax.

[scarlet1967]

I think not sharing anything about 1b is not helpful because people will anticipate the worst possible scenario which may or may not be true and as you mentioned there were obviously some issues which have to be addressed and they seem to believe they have dealt with it based on their analysis justifying the restart yet they don't want to share it? ! Anyway it is interesting that the

[Wino115]

The sciene guys can chime in, but I think from a pure research standpoint, clinical investigators look at each part of a trial as a very separate experiement with it's own questions, data and answers.  You pay the CRO to tabulate all that data, report it out and then you base your conclusions and hypothesis around that data. The first part was fully self-contained and they got all that

[scarlet1967]

    Yes she is involved with targeted drug delivery clinically, apart from being co author of few publications in the space this is what she said about Cyberexa's PDC. Her quote was included in their PR!!         "In this phase I study, CBX-12 demonstrated safety and tolerability, without significant gastrointestinal

[qwerty22]

I agree with paragraph 1 and 2 100%. I think you are right about 1a and 1b being separate entities. "I'm encouraged they actually put it all together and wrote it up." I think there is something close to an obligation to do this whether successful or not given the participation of human subjects. So it's not so surprising they are putting out a poster. At best maybe it'

[qwerty22]

One other thought is yes it will only be a bunch of tables and graphs but it should be the whole truth. So we should get a fuller understanding of the side effects. Plus beyond the three "responders" what happened with the rest of the cohort. Did they mostly only get one or two drug cycles? We know there are problems, we dont know exactly how much promise there was from this cohort, that

[Wino115]

Yes, and I'd like to know a lot of the baseline data - especially which cancer/tumor types since that appears to have become more meaningful and some may drop out, prior treatment types (since we know a few clash now), and especially what kind of physical shape many were in. The anecdotes we know of saw some extremely advanced patients and they never proceeded beyond a few doses for whatever